IGF-1 LR3
Also known as: Long R3 IGF-1, Long Arginine 3-IGF-1
Studied in published research — not a medical recommendation. Primary protocol (Standard Research Protocol): 20–50 mcg, Once daily (post-training or AM).
Once daily (post-training or AM)
Research-reported range (no primary dosing study). Short 4-week cycles prevent receptor downregulation; monitor blood glucose closely
Subcutaneous or intramuscular
Published peer-reviewed research & clinical protocols
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 250 doses in the vial at the low end (100 doses at the high end).
Save IGF-1 LR3 to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
IGF-1 LR3 supplier & $/mg comparison.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a Peptide?
A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.
Bottom Line Up Front
IGF-1 LR3 is a long-acting analog of insulin-like growth factor 1. It has potent anabolic effects. Banned in sports. High risk of side effects including hypoglycemia and organ growth.
Muscle growth, recovery
Safe long-term use, healthy aging
None
15 (4 human)
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. IGF-1 LR3 is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
IGF-1 LR3 is an 83-amino-acid recombinant analog of human Insulin-Like Growth Factor-1 featuring a 13-amino-acid N-terminal extension and an Arginine substitution at position 3. These modifications drastically reduce binding to IGF-binding proteins (IGFBPs), extending its half-life from ~20 minutes to 20–30 hours and increasing biological potency ~3x.
Mechanisms of Action
- Binds IGF-1R and insulin receptors to activate PI3K/Akt/mTOR protein synthesis pathways
- Evades serum IGFBP-1 through IGFBP-6 sequestration due to Glu3->Arg3 substitution
- Stimulates satellite cell proliferation and nitrogen retention in skeletal muscle
- Enhances glucose and amino acid uptake into myocytes
Research Protocols
Summaries of published research. For educational purposes only.
| Protocol Name | Source | Dose | Frequency | Duration | Route | Evidence | Link | Save |
|---|---|---|---|---|---|---|---|---|
| Standard Research Protocol | reported protocol | 20–50 mcg | Once daily (post-training or AM) | 4 weeks on, 4 weeks off | Subcutaneous or intramuscular | animal | — |
GH / IGF-1 & Glycemic Sensitivity Biomarker Panel (IGF-1 LR3)
Growth hormone secretagogues and somatomedin analogs directly elevate hepatic IGF-1 and can shift fasting insulin sensitivity via GH counter-regulatory signaling.
Serum IGF-1 (LC/MS) + Z-Score
Day 0 + Wk 6–8Why track at baseline: Establishes baseline somatotropic output before pituitary or local IGF-1R stimulation.
Week 6–8 check: Confirm physiological upper-quartile elevation (typically +30% to +80% above baseline) without supraphysiological overshoot (>300 ng/mL).
Fasting Insulin & HOMA-IR
Day 0 + Wk 6–8Why track at baseline: Pituitary GH pulses promote free fatty acid mobilization, which can transiently reduce peripheral insulin sensitivity.
Week 6–8 check: Keep Fasting Insulin <6–8 uIU/mL; if elevated, enforce strict 2–3 hr pre-bed fasting before GH secretagogue administration.
HbA1c & Fasting Plasma Glucose
Day 0 + Wk 6–8Why track at baseline: Screens for subclinical prediabetes prior to growth-factor or secretagogue exposure.
Week 6–8 check: Verify stable 90-day glycemic control (HbA1c <5.4% optimal) at Week 6–8.
hs-CRP, Prolactin & CMP
Day 0 + Wk 6–8Why track at baseline: Checks systemic inflammation, pituitary selectivity (no off-target prolactin/cortisol rise), and hepatic/renal clearance.
Week 6–8 check: Confirm Ipamorelin/CJC/Tesamorelin selectivity with unchanged Prolactin and normal liver transaminases.
Related Studies
We speculate that maintaining amino acid concentrations or raising insulin, glucose, and/or oxygen concentrations to values consistent with normally growing fetuses during IGF-1 LR3 treatment may be necessary to increase fetal growth in the setting of placental insufficiency and FGR.NEW & NOTEWORTHY IGF-1 LR3 treatment administered directly into growth-restricted fetal sheep circulation did not improve fetal growth or attenuate circulating insulin or fetal GSIS. Importantly, IGF-1 LR3 treatment reduced circulating amino acids, notably branched-chain amino acids, which have been shown to potentiate GSIS and protein accretion supporting fetal growth.
Limitations: Animal study only — human translation uncertain.
In male 5XFAD mice, IN LR3-IGF-1 treatment improved body composition, but did not significantly alter cognitive symptoms, as assessed by multiple assays. In cortex, LR3 treatment improved some facets of pathology, including a reduction in filamentous plaques, and increase in inert plaques, corresponding with a reduction in low molecular weight Aβ oligomers.
Limitations: No placebo control reported.
The IGF-1 LR3-controlled releasing decellularized conduit significantly improved axonal regeneration and showed comparable performance to autologous nerve grafts, without inducing systemic toxicity. This novel conduit demonstrates the potential of plant-based biomaterials for effective peripheral nerve repair.
Limitations: Animal study only — human translation uncertain.
Hepatic and muscular gene expression of IGFBPs one to three was similar between oIGF-1 and SAL. We conclude that oIGF-1 promotes tissue and organ-specific growth in the normal sheep fetus.
Limitations: In-vitro study — may not reflect in-vivo effects.
• Purified IGF-1 and LR3 IGF-1 show bioactivity comparable to the standard IGF-1. • High heterologous expression of IGF-1 and LR3 IGF-1 is achieved by fermentation in a bioreactor.
Limitations: No placebo control reported.
Therefore, we speculate that while acute IGF-1 LR3 infusion may directly suppress insulin secretion, the fetal β-cell in vitro retains the ability to recover GSIS. This may have important implications when considering the long-term effects of treatment modalities for fetal growth restriction.
Limitations: Animal study only — human translation uncertain.
The work suggests a novel mechanism for the activation of IGF-1 dependent ERK signaling in CHO cells, wherein IQGAP1 plausibly functions as an IGF-1R-associated scaffold protein. Appropriate glycosylation by the enzymes MGAT1 and MGAT5 is thus essential for processing of cell surface receptor IGF-1R, a potential binding partner in IQGAP1 and ERK signaling, the integral components of the IGF pathway.
Limitations: Animal study only — human translation uncertain.
We conclude that IGF-1-stimulated fetal myocardial growth is accompanied by appropriate expansion and function of the coronary vasculature. These findings support IGF-1 as a potential strategy to increase cardiac myocyte and coronary vascular endowment at birth.
Limitations: Animal study only — human translation uncertain.
IGF-1 infusion to fetal sheep increases organ growth but not by stimulating nutrient transfer to the fetus.
Animal StudyIn summary, LR3 IGF-1 infusion for 1 wk into late gestation fetal sheep increased the weight of some fetal organs. However, because umbilical amino acid uptake rates and fetal plasma amino acid concentrations were lower in the LR3 IGF-1 group, we speculate that animals treated with LR3 IGF-1 can efficiently utilize available nutrients to support organ-specific growth in the fetus rather than by stimulating placental blood flow or nutrient transfer to the fetus.NEW & NOTEWORTHY After a 1-wk infusion of LR3 IGF-1, late gestation fetal sheep had lower umbilical uptake rates of amino acids, lower fetal arterial amino acid and insulin concentrations, and lower fetal oxygen content; however, LR-3 IGF-1-treated fetuses were still able to effectively utilize the available nutrients and oxygen to support organ growth and myoblast proliferation.
Limitations: Animal study only — human translation uncertain.
Impaired insulin secretion persists in isolated fetal islets indicating an intrinsic islet defect in insulin release when exposed to IGF-1 LR3 infusion for 1 wk. We speculate this alteration in the insulin/IGF-1 axis contributes to the long-term reduction in β-cell function in neonates born with elevated IGF-1 concentrations following pregnancies complicated by diabetes or other conditions associated with fetal overgrowth.NEW & NOTEWORTHY After a 1-wk infusion of IGF-1 LR3, late gestation fetal sheep had lower plasma insulin and glucose concentrations, reduced fetal glucose-stimulated insulin secretion, and decreased fractional insulin secretion from isolated fetal islets without differences in pancreatic insulin content.
Limitations: Animal study only — human translation uncertain.
Epidermal growth factor receptor is required for estradiol-stimulated bovine satellite cell proliferation.
Animal StudyTransactivation of EGFR may directly stimulate proliferation, or EGFR may function to maintain the level of IGFR-1β which is necessary for E2-stimulated proliferation. It also is possible that the role of EGFR in E2-stimulated BSC proliferation may involve both of these mechanisms.
Limitations: Animal study only — human translation uncertain.
In advanced plaques, Long R3 IGF-1 increased the vSMC content of the plaque by more than twofold and significantly reduced the rate of intraplaque hemorrhage. We believe that IGF-1 in atherosclerotic plaques may have a role in preventing plaque instability, not only by modulating smooth muscle cell turnover, but also by altering smooth muscle cell phenotype.
Limitations: No placebo control reported.
Similarly, MCF7 xenografts were inhibited more effectively by the IGF-methotrexate conjugate than free methotrexate, even at a 4-fold lower molar dosage. Our results suggest that the targeting of the IGF receptor on tumor cells and tumor-related tissues with IGF-chemotherapy conjugates may substantially increase the specific drug localization and therapeutic effect in the tumor.
Limitations: No placebo control reported.
Increased plasma concentrations of a 31-32-kDa IGF-binding protein (possibly IGF-binding protein-1) in the treated group was detected by radioligand blot. We found that Long(R3)-IGF-1 infusion tended to preserve whole-body and muscle protein in beef heifers on a low-quality diet, and suggest that further investigation of this treatment may provide an alternative approach to reducing weight loss during the dry season.
Limitations: Animal study only — human translation uncertain.
The formation of one or both of these complexes may be important for the potent mitogenic action of this steroid. That estradiol stimulated a decrease of IRS-2, but not of IRS-1, suggests that these docking proteins have different roles in hormone-induced signaling in the uterus.
Limitations: Animal study only — human translation uncertain.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •Potent hypoglycemic potential — monitor blood glucose and have carbohydrates available
- •Mitogenic growth factor — strictly contraindicated in any history of malignancy
- •Banned by WADA at all times
Where to get IGF-1 LR3, baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Where to buy IGF-1 LR3: best verified price
Prices checked Nov 11, 2026 · sorted by $/mg · RUO
- 1. Swift Peptides — $84.99/mg (1mg vial, $84.99)
- 2. Elite Research USA — $85.00/mg (1mg vial, $85.00)
- 3. Polaris Peptides — $85.00/mg (1mg vial, $85.00)
Where is the cheapest place to buy IGF-1 LR3?
As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Swift Peptides at $84.99/mg (1mg vial, $84.99). We compared 6 US suppliers with live, checked prices.
How much does IGF-1 LR3 cost per mg?
Verified US domestic prices currently range from $84.99/mg to $150.00/mg depending on supplier and vial size. Larger vials usually lower the $/mg.
How are these prices verified?
Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.
Is IGF-1 LR3 approved for human use?
Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.
All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Related Peptides
More hormonal peptides
CJC-1295 (No DAC / Mod GRF 1-29)
CJC-1295 is a synthetic analog of growth hormone-releasing h...
Ipamorelin
Ipamorelin is a growth hormone secretagogue that selectively...
GHRP-2 (Pralmorelin)
GHRP-2 is a synthetic growth hormone-releasing peptide that ...
GHRP-6
GHRP-6 is a first-generation growth hormone-releasing peptid...
Hexarelin
Hexarelin is a synthetic growth hormone-releasing peptide (G...
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.